Boston Scientific Corporation (BSX)
Wall Street Analysts Believe Boston Scientific (BSX) Could Rally 25.34%: Here's is How to Trade
The consensus price target hints at a 25.3% upside potential for Boston Scientific (BSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Boston Scientific Up 7% in a Month: How Should You Play the Stock?
BSX's month-long rally, strong Q3 beats and expansion into chronic pain solutions sharpen investor focus.
Boston Scientific (BSX) Crossed Above the 200-Day Moving Average: What That Means for Investors
Boston Scientific (BSX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BSX crossed above the 200-day moving average, suggesting a long-term bullish trend.
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Is Boston Scientific (BSX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Boston Scientific (BSX) could produce exceptional returns because of its solid growth attributes.
What's Behind Boston Scientific's Optimism for Urology Growth?
BSX sees stronger 2026 prospects for Urology, powered by Axonics integration, innovation and global Stone Management momentum.
Boston Scientific Sustains EP Momentum in Q3: Is More Upside Ahead?
BSX's Q3 EP sales soar 63% on FARAPULSE momentum, FDA label expansion and rising global adoption.
Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include The Chef's Warehouse, Life Time Group Holdings, The Honest Company, CorMedix and Boston Scientific.
Boston Scientific Q3: Operational Improvements Warrant An Upgrade To A Buy
Boston Scientific delivered strong Q3 results, with 20% revenue growth and beats on both top and bottom lines, prompting a rating upgrade to Buy. BSX's cardiovascular and MedSurg segments, driven by innovations like WATCHMAN and Farapulse, are fueling impressive growth and margin expansion. Management raised 2025 guidance, highlighting robust product demand, successful M&A strategy, and promising pipeline, especially in chronic pain and stroke prevention.
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Boston Scientific (BSX) Crossed Above the 200-Day Moving Average: What That Means for Investors
After reaching an important support level, Boston Scientific (BSX) could be a good stock pick from a technical perspective. BSX surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
Boston Scientific (BSX) Recently Broke Out Above the 50-Day Moving Average
From a technical perspective, Boston Scientific (BSX) is looking like an interesting pick, as it just reached a key level of support. BSX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
